Generally, when investors are looking for growth, they turn to industries like technology. Here, revenues may rise in double or even triple digits, leading to explosive stock performance. But in recent years, a unique area of the pharmaceutical market has presented such an opportunity. And it’s in the weight loss drug space. just now, Eli … Read more
In the last two years Eli Lilly (NYSE: LLY ) It has established itself as a leader in the weight loss market. This is thanks to the company’s Terzapatide, a compound sold under the name Zipbound as an anti-obesity drug (and Monjaro in the treatment of diabetes) that became the world’s best-selling drug in 2025. … Read more
In January, New Nordisk (NYSE: NVO ) Vigoi has broken new ground in the weight loss market by launching an oral version of its popular anti-obesity drug. It is the first oral GLP-1 approved for long-term weight management, and Novo Nordisk hopes it will help it regain market share in this area. While Oral Vigovi … Read more